BioSpace News Archive

Feldan Therapeutics, a biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics, has announced the initial closing of a $16.5 million Series B investment.

RaySearch Laboratories AB is pleased to announce a strategic collaboration agreement with B dot Medical Inc. aimed at advancing the field of proton therapy by development and validation of intregrations between RaySearch’s treatment planning system RayStation®*, oncology information system RayCare®* and B dot Medical’s ultra-compact proton therapy system.

Foresight Diagnostics announced that Mark Roschewski, MD, of the National Cancer Institute, part of the National Institutes of Health, will present pooled data from six recent clinical studies on June 14th at the 17th International Conference on Malignant Lymphoma in Lugano, Switzerland.

ImmunoPrecise Antibodies Ltd., a leader in AI-driven biotherapeutic research and technology, is excited to announce a new use case for the Information Integration Dilemma solution developed by its subsidiary, BioStrand®.

Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced the publication of survey data describing clinician preferences among oxybate treatments for patients living with narcolepsy.

X4 Pharmaceuticals announced that it expects to be added to the broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023, according to a preliminary list of additions posted on June 9, 2023.

Viridian Therapeutics, Inc. announced that multiple abstracts featuring data on the Company’s lead investigational therapy for the treatment of thyroid eye disease will be presented at the Annual Meeting of the Endocrine Society to be held June 15-18, 2023, in Chicago, Illinois.

Panbela Therapeutics, Inc . (Nasdaq: PBLA) today announced it has entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center for the evaluation of polyamine metabolic inhibitor therapies in combination with CAR-T cell therapies in preclinical models.

Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, announced the appointment of Dr. Todd McMullen as the company’s new Medical Laboratory Director.

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the first patient has been administered on June 5, in a Phase 1 clinical trial, evaluating OLX72021, an investigational RNAi therapeutic intended for the treatment of androgenic alopecia, also known as male-pattern baldness.